NCT07018076 Candidate Clinical Correlate of Prognostic Outcome for TB Study
| NCT ID | NCT07018076 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Tuberculosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2025-11-25 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.
Eligibility Criteria
Inclusion Criteria: 1. . individuals age ≥ 12 years; 2. . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). Exclusion Criteria: 1. completed treatment for drug-susceptible tuberculosis \>14 days prior to screening/enrollment; 2. routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days; 3. unwilling to provide informed consent or return for study follow-up visits.
Contact & Investigator
Adithya Cattamanchi, MD
PRINCIPAL INVESTIGATOR
University of California San Francisco; University of California Irvine
Frequently Asked Questions
Who can join the NCT07018076 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07018076 currently recruiting?
Yes, NCT07018076 is actively recruiting participants. Contact the research team at adithya.cattamanchi@ucsf.edu for enrollment information.
Where is the NCT07018076 trial being conducted?
This trial is being conducted at Kampala, Uganda, Kampala, Uganda, Hanoi, Vietnam.
Who is sponsoring the NCT07018076 clinical trial?
NCT07018076 is sponsored by University of California, San Francisco. The principal investigator is Adithya Cattamanchi, MD at University of California San Francisco; University of California Irvine. The trial plans to enroll 750 participants.